acute myeloid leukemia
FDA Approves Preparative Regimen for allo-HSCT in Patients With AML or MDS
The FDA has approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative ...
FEBRUARY 19, 2025
Continuous Temperature Monitoring Could Detect Febrile Neutropenia
Remote temperature monitoring devices may enable early detection of febrile neutropenia in adults with AML who have ...
JUNE 5, 2024
Phase 3 Trial Validates FLT3-ITD MRD as Target for FLT3-ITD-Positive AML
New findings demonstrate the prognostic utility of FLT3-ITD-specific MRD measurements in the clinical management of ...
JANUARY 22, 2024
Vanflyta Approved for Newly Diagnosed Acute Myeloid Leukemia
The FDA approved quizartinib (Vanflyta, Daiichi Sankyo) with standard cytarabine and anthracycline induction and ...
JULY 24, 2023
Decitabine Shines in Study of AML Patients
Patients with acute myeloid leukemia (AML) who are older and fit who get pretreated with a 10-day regimen of ...
SEPTEMBER 23, 2022
Quizartinib Poised to Change Treatment Paradigm for AML
Adding quizartinib (Daiichi Sankyo) to standard chemotherapy and consolidation significantly improves overall ...
JULY 13, 2022
Guide Identifies AML Patients at Risk for Early Treatment-Related Death
A risk stratification guide could help clinicians select the optimal intensity of chemotherapy for patients with ...
MAY 27, 2022
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
Maximizing the Benefit of Venetoclax in AML
The approval of venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine provides ...
AUGUST 23, 2021
Onureg, Oral Formulation of Azacitidine, Approved for AML
The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid ...
SEPTEMBER 4, 2020
Report From ASH 2019: Oral Azacitidine Formulation Extends First Remissions in AML
ORLANDO, FLA.—A novel oral formulation of azacitidine produced a highly significant improvement in overall ...
DECEMBER 19, 2019
FDA Approves Ivosidenib as First-Line Therapy for AML
The agency reviewed the application for ivosidenib using its Real-Time Oncology Review pilot program.
MAY 3, 2019